The risk for Clostridium difficile colitis during hospitalization in asymptomatic carriers - 18/04/17
Doi : 10.1016/j.jhin.2017.01.013
S. Kagan a, Y. Wiener-Well a, ⁎ 
, E. Ben-Chetrit a, L. Kashat b, J. Aouizerats b, T. Bdolah-Abram c, A.M. Yinnon a, d, M.V. Assous b
, E. Ben-Chetrit a, L. Kashat b, J. Aouizerats b, T. Bdolah-Abram c, A.M. Yinnon a, d, M.V. Assous b a Infectious Disease Unit, Shaare Zedek Medical Center, Affiliated with the Hebrew University Hadassah Medical School, Jerusalem, Israel
b Clinical Microbiology Laboratory, Shaare Zedek Medical Center, Affiliated with the Hebrew University Hadassah Medical School, Jerusalem, Israel
c Hebrew University Hadassah Medical School, Jerusalem, Israel
d Division of Internal Medicine, Shaare Zedek Medical Center, Affiliated with the Hebrew University Hadassah Medical School, Jerusalem, Israel
∗Corresponding author. Address: Shaare Zedek Medical Center, Infectious Disease Unit, P.O. Box 3235, Jerusalem 91301, Israel. Tel.: +972 2 6555332; fax: +972 2 6666840.Shaare Zedek Medical CenterInfectious Disease UnitP.O. Box 3235Jerusalem91301Israel
Le texte complet de cet article est disponible en PDF.
Plan
© 2017
The Healthcare Infection Society. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 95 - N° 4
P. 442-443 - avril 2017 Retour au numéro
Article précédent
- Treatment of Clostridium difficile infection: a national survey of clinician recommendations and the use of faecal microbiota transplantation
- A.R. Prior, D. Kevans, L. McDowell, S. Cudmore, F. Fitzpatrick
- National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK
- M.N. Quraishi, J. Segal, B. Mullish, V.L. McCune, P. Hawkey, A. Colville, H. Williams, A. Hart, T.H. Iqbal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?